Management of patients with hepatitis B and C before and after liver and kidney transplantation

World Journal of Hepatology

Volumn 6, Issue 5, 2014, Pages 315-325

  Pipili, Chrysoula ^a   Cholongitas, Evangelos ^b  

^a Department of Nephrology Laiki Merimna ^*  (Greece)

^b ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

Author keywords

Hepatitis B; Hepatitis C; Kidney transplantation; Liver transplantation; Recurrence

Indexed keywords

EID: 84901454701     PISSN: None     EISSN: 19485182     Source Type: Journal    
DOI: 10.4254/wjh.v6.i5.315     Document Type: Article

References (137)

1. Pham PT, Pham PA, Pham PC, Parikh S, Danovitch G. Evaluation of adult kidney transplant candidates. Semin Dial 2010; 23: 595-605 [PMID: 21175834 DOI: 10.1111/j.1525-139X.2010.00809.x].
2. Shibolet O, Ilan Y, Gillis S, Hubert A, Shouval D, Safadi R. Lamivudine therapy for prevention of immunosuppressiveinduced hepatitis B virus reactivation in hepatitis B surface antigen carriers. Blood 2002; 100: 391-396 [PMID: 12091327 DOI: 10.1182/blood.V100.2.391].
3. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294-1305 [PMID: 19619264 DOI: 10.1111/j.1478-3231.2009.02085.x].
4. Samuel D. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004; 24 Suppl 1: 55-62 [PMID: 15192802 DOI: 10.1055/s-2004-828679].
5. Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Threeyear efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology 2011; 140: 132-143 [PMID: 20955704 DOI: 10.1053/j.gastro.2010.10.011].
6. Schiff E, Simsek H, Lee WM, Chao YC, Sette H, Janssen HL, Han SH, Goodman Z, Yang J, Brett-Smith H, Tamez R. Efficacy and safety of entecavir in patients with chronic hepatitis B and advanced hepatic fibrosis or cirrhosis. Am J Gastroenterol 2008; 103: 2776-2783 [PMID: 18721244 DOI: 10.1111/j.1572-0241.2008.02086.x].
7. Papatheodoridis GV, Manolakopoulos S, Dusheiko G, Archimandritis AJ. Therapeutic strategies in the management of patients with chronic hepatitis B virus infection. Lancet Infect Dis 2008; 8: 167-178 [DOI: 10.1016/S1473-3099(07)70264-5].
8. McGovern BH, Abu Dayyeh BK, Chung RT. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. Hepatology 2008; 48: 1700-1712 [PMID: 18972443 DOI: 10.1002/hep.22563].
9. Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013; 28: 38-45 [PMID: 23137126 DOI: 10.1111/jgh.12028].
10. Garg V, van Heeswijk R, Lee JE, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-27 [PMID: 21618566 DOI: 10.1002/hep.24443].
11. Verna EC, Brown RS. Hepatitis C virus and liver transplantation. Clin Liver Dis 2006; 10: 919-940 [PMID: 17164125 DOI: 10.1016/j.cld.2006.08.012].
12. Bzowej N, Nelson DR, Terrault NA, Everson GT, Teng LL, Prabhakar A, Charlton MR. PHOENIX: A randomized controlled trial of peginterferon alfa-2a plus ribavirin as a prophylactic treatment after liver transplantation for hepatitis C virus. Liver Transpl 2011; 17: 528-538 [PMID: 21506241 DOI: 10.1002/lt.22271].
13. Roche B, Samuel D. Hepatitis C virus treatment pre-and post-liver transplantation. Liver Int 2012; 32 Suppl 1: 120-128 [PMID: 22212582 DOI: 10.1111/j.1478-3231.2011.02714.x].
14. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc 2007; 39: 3276-3280 [PMID: 18089370 DOI: 10.1016/j.transproceed.2007.07.085].
15. Papatheodoridis GV, Sevastianos V, Burroughs AK. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003; 3: 250-258 [PMID: 12614278 DOI: 10.1034/j.1600-6143.2003.00063.x].
16. Fabrizi F, Martin P, Dixit V, Kanwal F, Dulai G. HBsAg seropositive status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant 2005; 5: 2913-2921 [PMID: 16303005 DOI: 10.1111/j.1600-6143.2005.01113.x].
17. Picciotto FP, Tritto G, Lanza AG, Addario L, De Luca M, Di Costanzo GG, Lampasi F, Tartaglione MT, Marsilia GM, Calise F, Cuomo O, Ascione A. Sustained virological response to antiviral therapy reduces mortality in HCV reinfection after liver transplantation. J Hepatol 2007; 46: 459-465 [PMID: 17196700 DOI: 10.1016/j.jhep.2006.10.017].
18. Roche B, Sebagh M, Canfora ML, Antonini T, Roque-Afonso AM, Delvart V, Saliba F, Duclos-Vallee JC, Castaing D, Samuel D. Hepatitis C virus therapy in liver transplant recipients: response predictors, effect on fibrosis progression, and importance of the initial stage of fibrosis. Liver Transpl 2008; 14: 1766-1777 [PMID: 19025933 DOI: 10.1002/lt.21635].
19. Ramachandran P, Fraser A, Agarwal K, Austin A, Brown A, Foster GR, Fox R, Hayes PC, Leen C, Mills PR, Mutimer DJ, Ryder SD, Dillon JF. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012; 35: 647-662 [PMID: 22296568 DOI: 10.1111/j.1365-2036.2012.04992.x].
20. Chan HL, Chen YC, Gane EJ, Sarin SK, Suh DJ, Piratvisuth T, Prabhakar B, Hwang SG, Choudhuri G, Safadi R, Tanwandee T, Chutaputti A, Yurdaydin C, Bao W, Avila C, Trylesinski A. Randomized clinical trial: efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-743 [PMID: 22967105 DOI: 10.1111/j.1365-2893.2012.01600.x].
21. Fontana RJ, Hann HW, Perrillo RP, Vierling JM, Wright T, Rakela J, Anschuetz G, Davis R, Gardner SD, Brown NA. Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy. Gastroenterology 2002; 123: 719-727 [PMID: 12198698 DOI: 10.1053/gast.2002.35352].
22. Liaw YF, Raptopoulou-Gigi M, Cheinquer H, Sarin SK, Tanwandee T, Leung N, Peng CY, Myers RP, Brown RS, Jeffers L, Tsai N, Bialkowska J, Tang S, Beebe S, Cooney E. Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: a randomized, openlabel study. Hepatology 2011; 54: 91-100 [PMID: 21503940 DOI: 10.1002/hep.24361].
23. Fontana RJ, Keeffe EB, Carey W, Fried M, Reddy R, Kowdley KV, Soldevila-Pico C, McClure LA, Lok AS. Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl 2002; 8: 433-439 [PMID: 12004342 DOI: 10.1053/jlts.2002.32983].
24. Kapoor D, Guptan RC, Wakil SM, Kazim SN, Kaul R, Agarwal SR, Raisuddin S, Hasnain SE, Sarin SK: Beneficial effects of lamivudine in hepatitis B virus-related decompensated cirrhosis. J Hepatol 2000; 33: 308-312 [DOI: 10.1016/S0168-8278(00)80372-4].
25. Manolakopoulos S, Karatapanis S, Elefsiniotis J, Mathou N, Vlachogiannakos J, Iliadou E, Kougioumtzan A, Economou M, Triantos C, Tzourmakliotis D, Avgerinos A. Clinical course of lamivudine monotherapy in patients with decompensated cirrhosis due to HBeAg negative chronic HBV infection. Am J Gastroenterol 2004; 99: 57-63 [PMID: 14687142 DOI: 10.1046/j.1572-0241.2003.04021.x].
26. European Association For The Study Of The Liver. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol 2009; 50: 227-242 [PMID: 19054588 DOI: 10.1016/j.jhep.2008.10.001].
27. Liaw YF, Leung N, Kao JH, Piratvisuth T, Gane E, Han KH, Guan R, Lau GK, Locarnini S. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update. Hepatol Int 2008; 2: 263-283 [PMID: 19669255 DOI: 10.1007/s12072-008-9080-3].
28. Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology 2009; 50: 661-662 [PMID: 19714720 DOI: 10.1002/hep.23190].
29. Kim IS, Mun JI, Koo JH, Kang CJ, Bak JK, Cheong JY, Cho SW. [Entecavir therapy for patients with hepatitis B virusrelated decompensated cirrhosis]. Korean J Gastroenterol 2012; 59: 224-231 [PMID: 22460571 DOI: 10.4166/kjg.2012.59.3.224].
30. Sadler MD, Coffin CS, Lee SS. Entecavir for the treatment of patients with hepatitis B virus-related decompensated cirrhosis. Expert Opin Pharmacother 2013; 14: 1363-1369 [PMID: 23557465 DOI: 10.1517/14656566.2013.786701].
31. Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: meta-analysis. World J Gastroenterol 2013; 19: 6665-6678 [PMID: 24151397 DOI: 10.3748/wjg.v19.i39.6665].
32. Marcellin P, Gane E, Buti M, Afdhal N, Sievert W, Jacobson IM, Washington MK, Germanidis G, Flaherty JF, Schall RA, Bornstein JD, Kitrinos KM, Subramanian GM, McHutchison JG, Heathcote EJ. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381: 468-475 [PMID: 23234725 DOI: 10.1016/S0140-6736(12)61425-1].
33. Marcellin P, Heathcote EJ, Buti M, Gane E, de Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Washington MK, Sorbel J, Anderson J, Snow-Lampart A, Mondou E, Quinn J, Rousseau F. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B. N Engl J Med 2008; 359: 2442-2455 [PMID: 19052126 DOI: 10.1056/NEJMoa0802878].
34. Wong VW, Chan FK. Regression of cirrhosis with longterm tenofovir treatment. Gastroenterology 2013; 145: 481-482 [PMID: 23791793 DOI: 10.1053/j.gastro.2013.06.019].
35. Liaw YF, Sheen IS, Lee CM, Akarca US, Papatheodoridis GV, Suet-Hing Wong F, Chang TT, Horban A, Wang C, Kwan P, Buti M, Prieto M, Berg T, Kitrinos K, Peschell K, Mondou E, Frederick D, Rousseau F, Schiff ER. Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72 [PMID: 21254162 DOI: 10.1002/hep.23952].
36. Izzedine H, Hulot JS, Vittecoq D, Gallant JE, Staszewski S, Launay-Vacher V, Cheng A, Deray G. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naive HIV-1-infected patients. Data from a double-blind randomized active-controlled multicentre study. Nephrol Dial Transplant 2005; 20: 743-746 [PMID: 15741212 DOI: 10.1093/ndt/gfh658].
37. Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis 2013; 56: 567-575 [PMID: 23143096 DOI: 10.1093/cid/cis937].
38. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14: 479-487 [PMID: 22624695 DOI: 10.1111/j.1399-3062.2012.00741.x].
39. European Association For The Study Of The Liver. EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185 [PMID: 22436845].
40. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539 [PMID: 17256718 DOI: 10.1002/hep.21513].
41. Parshutin NP, Korsakov SG. Comparative analysis of the data of acupuncture electrodiagnosis and hormonal status of women with oligomenorrhea. Akush Ginekol (Mosk) 1990; (6): 26-29
42. Chalasani N, Manzarbeitia C, Ferenci P, Vogel W, Fontana RJ, Voigt M, Riely C, Martin P, Teperman L, Jiao J, Lopez-Talavera JC. Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology 2005; 41: 289-298 [PMID: 15660392 DOI: 10.1002/hep.20560]
43. Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, Coppa J, Romito R, Burgoa L, Zucchini N, Urbanek T, Bonino F. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001; 33: 1355-1357 [PMID: 11267325 DOI: 10.1016/S0041-1345(00)02508-2].
44. Shergill AK, Khalili M, Straley S, Bollinger K, Roberts JP, Ascher NA, Terrault NA. Applicability, tolerability and efficacy of preemptive antiviral therapy in hepatitis C-infected patients undergoing liver transplantation. Am J Transplant 2005; 5: 118-124 [PMID: 15636619 DOI: 10.1111/j.1600-6143.2004.00648.x].
45. Sugawara Y, Makuuchi M, Matsui Y, Kishi Y, Akamatsu N, Kaneko J, Kokudo N. Preemptive therapy for hepatitis C virus after living-donor liver transplantation. Transplantation 2004; 78: 1308-1311 [PMID: 15548968 DOI: 10.1097/01. TP.0000142677.12473.E5].
46. Selzner N, Guindi M, Renner EL, Berenguer M. Immunemediated complications of the graft in interferon-treated hepatitis C positive liver transplant recipients. J Hepatol 2011; 55: 207-217 [PMID: 21145865 DOI: 10.1016/j.jhep.2010.11.012].
47. Rubín A, Aguilera V, Berenguer M. Liver transplantation and hepatitis C. Clin Res Hepatol Gastroenterol 2011; 35: 805-812 [PMID: 21963086 DOI: 10.1016/j.clinre.2011.04.009].
48. Laryea MA, Watt KD. Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation. Liver Transpl 2012; 18: 514-523 [PMID: 22315212 DOI: 10.1002/lt.23408].
49. Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: a systematic review. Am J Transplant 2013; 13: 353-362 [PMID: 23137006 DOI: 10.1111/j.1600-6143.2012.04315.x].
50. Perrillo R, Buti M, Durand F, Charlton M, Gadano A, Cantisani G, Loong CC, Brown K, Hu W, Lopez-Talavera JC, Llamoso C. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl 2013; 19: 887-895 [PMID: 23788462 DOI: 10.1002/lt.23690].
51. Ahn J, Cohen SM. Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin. Hepat Mon 2011; 11: 638-645 [PMID: 22140388 DOI: 10.5812/kowsar.1735143X.1010].
52. Fung J, Cheung C, Chan SC, Yuen MF, Chok KS, Sharr W, Dai WC, Chan AC, Cheung TT, Tsang S, Lam B, Lai CL, Lo CM. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219 [PMID: 21762659 DOI: 10.1053/j.gastro.2011.06.083].
53. Perrillo R BM, Durand F. Safety and efficacy of entecavir in patients receiving liver transplantation due to chronic hepatitis B. J Hepatol 2012; 56: S212 [DOI: 10.1016/S0168-8278(12)60548-0].
54. Wadhawan M VV, Goyal N, Dargan P, Rastogi M, Vasu F. Living related liver transplant (LRLT) in HBV DNA negative cirrhosis without hepatitis B immune globulin (HBIG). Hepatol Int 2011; 5: S38
55. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: a systematic review. Liver Transpl 2011; 17: 1176-1190 [PMID: 21656655 DOI: 10.1002/lt.22354].
56. Lake JR. Do we really need long-term hepatitis B hyperimmune globulin? What are the alternatives? Liver Transpl 2008; 14 Suppl 2: S23-S26 [PMID: 18825722 DOI: 10.1002/lt.21637].
57. Shouval D, Samuel D. Hepatitis B immune globulin to prevent hepatitis B virus graft reinfection following liver transplantation: a concise review. Hepatology 2000; 32: 1189-1195 [PMID: 11093723 DOI: 10.1053/jhep.2000.19789].
58. Lenci I, Tisone G, Di Paolo D, Marcuccilli F, Tariciotti L, Ciotti M, Svicher V, Perno CF, Angelico M. Safety of complete and sustained prophylaxis withdrawal in patients livertransplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55: 587-593 [PMID: 21251938 DOI: 10.1016/j.jhep.2010.12.036].
59. Berenguer M, Prieto M, Rayón JM, Mora J, Pastor M, Ortiz V, Carrasco D, San Juan F, Burgueño MD, Mir J, Berenguer J. Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation. Hepatology 2000; 32: 852-858 [PMID: 11003634 DOI: 10.1053/jhep.2000.17924].
60. Gurusamy KS, Tsochatzis E, Xirouchakis E, Burroughs AK, Davidson BR. Antiviral therapy for recurrent liver graft infection with hepatitis C virus. Cochrane Database Syst Rev 2010; (1): CD006803 [PMID: 20091608].
61. Coilly A, Roche B, Samuel D. Current management and perspectives for HCV recurrence after liver transplantation. Liver Int 2013; 33 Suppl 1: 56-62 [PMID: 23286847 DOI: 10.1111/liv.12062].
62. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996; 24: 289-293 [PMID: 8690394 DOI: 10.1002/hep.510240201].
63. Blasco A, Forns X, Carrión JA, García-Pagán JC, Gilabert R, Rimola A, Miquel R, Bruguera M, García-Valdecasas JC, Bosch J, Navasa M. Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology 2006; 43: 492-499 [PMID: 16496308 DOI: 10.1002/hep.21090].
64. Carrión JA, Torres F, Crespo G, Miquel R, García-Valdecasas JC, Navasa M, Forns X. Liver stiffness identifies two different patterns of fibrosis progression in patients with hepatitis C virus recurrence after liver transplantation. Hepatology 2010; 51: 23-34 [PMID: 19839063 DOI: 10.1002/hep.23240].
65. Forman LM, Lewis JD, Berlin JA, Feldman HI, Lucey MR. The association between hepatitis C infection and survival after orthotopic liver transplantation. Gastroenterology 2002; 122: 889-896 [PMID: 11910340 DOI: 10.1053/gast.2002.32418].
66. Fukuhara T, Taketomi A, Motomura T, Okano S, Ninomiya A, Abe T, Uchiyama H, Soejima Y, Shirabe K, Matsuura Y, Maehara Y. Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C. Gastroenterology 2010; 139: 1577-1585, 1585 e1571-1573 [PMID: 20708617].
67. Gane EJ. The natural history of recurrent hepatitis C and what influences this. Liver Transpl 2008; 14 Suppl 2: S36-S44 [PMID: 18825724 DOI: 10.1002/lt.21646].
68. Humar A, Kumar D, Raboud J, Caliendo AM, Moussa G, Levy G, Mazzulli T. Interactions between cytomegalovirus, human herpesvirus-6, and the recurrence of hepatitis C after liver transplantation. Am J Transplant 2002; 2: 461-466 [PMID: 12123213 DOI: 10.1034/j.1600-6143.2002.20511.x].
69. Berenguer M. Systematic review of the treatment of established recurrent hepatitis C with pegylated interferon in combination with ribavirin. J Hepatol 2008; 49: 274-287 [PMID: 18571272 DOI: 10.1016/j.jhep.2008.05.002].
70. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon-based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transplant 2006; 6: 1586-1599 [PMID: 16827859 DOI: 10.1111/j.1600-6143.2006.01362.x].
71. Xirouchakis E, Triantos C, Manousou P, Sigalas A, Calvaruso V, Corbani A, Leandro G, Patch D, Burroughs A. Pegylated-interferon and ribavirin in liver transplant candidates and recipients with HCV cirrhosis: systematic review and meta-analysis of prospective controlled studies. J Viral Hepat 2008; 15: 699-709 [PMID: 18673428 DOI: 10.1111/j.1365-2893.2008.01019.x].
72. Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC. Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience. J Hepatol 2014; 60: 78-86 [PMID: 23994384].
73. Pungpapong S, Aqel BA, Koning L, Murphy JL, Henry TM, Ryland KL, Yataco ML, Satyanarayana R, Rosser BG, Vargas HE, Charlton MR, Keaveny AP. Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation. Liver Transpl 2013; 19: 690-700 [PMID: 23696372 DOI: 10.1002/lt.23669].
74. Werner CR, Egetemeyr DP, Lauer UM, Nadalin S, Königsrainer A, Malek NP, Berg CP. Telaprevir-based triple therapy in liver transplant patients with hepatitis C virus: a 12-week pilot study providing safety and efficacy data. Liver Transpl 2012; 18: 1464-1470 [PMID: 22941516 DOI: 10.1002/lt.23542].
75. Stravitz T LJ, Dodge J, Saxena V, Burton J, Verna E, O'Leary J, Parikh N, Everson G, Brown R, Trotter J, Terrault N. Higher Sustained Virologic Response (SVR-12) Achievable in Liver Transplant (LT) Recipients with Hepatitis C (HCV) Treated with Protease Inhibitor (PI) Triple Therapy (TT). Hepatology 2013: 58 (4 suppl).
76. Ann Brown K FR, Russo M, Levitsky J, Yoshida E, Vargas H, Bsharat M, Rubin R, Brown R.: Twice-daily Telaprevir in combination with Peginterferon alfa 2a/ribavirin in genotype 1 HCV Liver Transplant recipients: Interim week 16 Safety and Efficacy Results on the Prospective, Multicenter REFRESH Study. Hepatology 2013; 58: AASLD abstracts.
77. Forns X FR, Moonka D, McHutchison J, Symonds W, Denning J, McNair L, Chang P, Kivett V, Shiffman M, Charlton M. Initial evaluation of Sofosbuvir compassionate use program for patients with severe recurrent HCV following liver transplantation. Hepatology 2013; 58 (4 suppl): 1084 AASLD abstracts.
78. Manousou P, Samonakis D, Cholongitas E, Patch D, O' Beirne J, Dhillon AP, Rolles K, McCormick A, Hayes P, Burroughs AK. Outcome of recurrent hepatitis C virus after liver transplantation in a randomized trial of tacrolimus monotherapy versus triple therapy. Liver Transpl 2009; 15: 1783-1791 [PMID: 19938143 DOI: 10.1002/lt.21907].
79. Samonakis DN, Cholongitas E, Triantos CK, Griffiths P, Dhillon AP, Thalheimer U, Patch DW, Burroughs AK. Sustained, spontaneous disappearance of serum HCV-RNA under immunosuppression after liver transplantation for HCV cirrhosis. J Hepatol 2005; 43: 1091-1093 [PMID: 16239045 DOI: 10.1016/j.jhep.2005.08.005].
80. Chan TM, Fang GX, Tang CS, Cheng IK, Lai KN, Ho SK. Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. Hepatology 2002; 36: 1246-1252 [PMID: 12395336 DOI: 10.1053/jhep.2002.36156].
81. Maluf DG, Fisher RA, King AL, Gibney EM, Mas VR, Cotterell AH, Shiffman ML, Sterling RK, Behnke M, Posner MP. Hepatitis C virus infection and kidney transplanta-tion: predictors of patient and graft survival. Transplantation 2007; 83: 853-857 [PMID: 17460555 DOI: 10.1097/01.tp.0000259725.96694.0a].
82. Ridruejo E, Adrover R, Cocozzella D, Reggiardo MV, Fernández N. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010; 51: 2231; author reply 2231-2232 [PMID: 20513017 DOI: 10.1002/hep.23714].
83. Santos L, Alves R, Macario F, Parada B, Campos M, Mota A. Impact of hepatitis B and C virus infections on kidney transplantation: a single center experience. Transplant Proc 2009; 41: 880-882 [PMID: 19376378 DOI: 10.1016/j.transproceed.20 09.01.074].
84. Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology 2002; 36: 3-10 [PMID: 12085342 DOI: 10.1053/jhep.2002.34613].
85. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004; 39: 1147-1171 [PMID: 15057920 DOI: 10.1002/hep.20119].
86. Pipili CL, Papatheodoridis GV, Cholongitas EC. Treatment of hepatitis B in patients with chronic kidney disease. Kidney Int 2013; 84: 880-885 [PMID: 23783238 DOI: 10.1038/ki.2013.249].
87. Fabrizi F, Aghemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int 2013; 84: 874-879 [PMID: 23823603 DOI: 10.1038/ki.2013.264].
88. Chopra A, Cantarovich M, Bain VG. Simultaneous liver and kidney transplants: optimizing use of this double resource. Transplantation 2011; 91: 1305-1309 [PMID: 21512431 DOI: 10.1097/TP.0b013e31821bad1b].
89. Numata A, Akimoto T, Toshima M, Iwazu Y, Otani N, Miki T, Sugase T, Saito O, Hamano Y, Takemoto F, Ueda Y, Muto S, Kusano E. Membranous nephropathy in an HIV-positive patient complicated with hepatitis B virus infection. Clin Exp Nephrol 2011; 15: 769-773 [PMID: 21713374 DOI: 10.1007/s10157-011-0477-2].
90. Olsen SK, Brown RS. Hepatitis B treatment: Lessons for the nephrologist. Kidney Int 2006; 70: 1897-1904 [PMID: 17021602].
91. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3: S1-S155 [DOI: 10.1111/j.1600-6143.2009.02834.x].
92. Fabrizi F BS, Martin P. Kidney transplantation and liver disease. In: Handbook of Kidney transplantation Edited by Danovitch G. 5th ed. Philadelphia: Lippincot Williams and Wilkins, 2010: 280-290.
93. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008; (109): S1-S99.
94. Mallet V, Gilgenkrantz H, Serpaggi J, Verkarre V, Vallet-Pichard A, Fontaine H, Pol S. Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 2008; 149: 399-403 [PMID: 18794559 DOI: 10.7326/0003-4819-149-6-200809160-00006].
95. Schmitz V, Kiessling A, Bahra M, Puhl G, Kahl A, Berg T, Neuhaus R, Neuhaus P, Neumann U. Peginterferon alfa-2b plus ribavirin for the treatment of hepatitis C recurrence following combined liver and kidney transplantation. Ann Transplant 2007; 12: 22-27 [PMID: 18290566].
96. Tseng PL, Chen TC, Chien YS, Hung CH, Yen YH, Chang KC, Tsai MC, Lin MT, Lee CT, Shen CH, Hu TH. Efficacy and safety of pegylated interferon alfa-2b and ribavirin combination therapy versus pegylated interferon monotherapy in hemodialysis patients: a comparison of 2 sequentially treated cohorts. Am J Kidney Dis 2013; 62: 789-795 [PMID: 23746377 DOI: 10.1053/j.ajkd.2013.03.037].
97. Fabrizi F, Dixit V, Martin P, Messa P. Combined antiviral therapy of hepatitis C virus in dialysis patients: meta-analysis of clinical trials. J Viral Hepat 2011; 18: e263-e269 [PMID: 21108701 DOI: 10.1111/j.1365-2893.2010.01405.x].
98. Dumortier J, Guillaud O, Gagnieu MC, Janbon B, Juillard L, Morelon E, Leroy V. Anti-viral triple therapy with telaprevir in haemodialysed HCV patients: is it feasible? J Clin Virol 2013; 56: 146-149 [PMID: 23149155 DOI: 10.1016/j.jcv.2012.10.009].
99. Knapstein J, Galle PR, Zimmermann T. Antiviral triple therapy with boceprevir in a chronic hepatitis C haemodialysis patient awaiting kidney re-transplantation. Dig Liver Dis 2014; 46: 88-89 [PMID: 24054768].
100. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805 [PMID: 7482738 DOI: 10.1097/00007890-199510000-00007].
101. Toth CM, Pascual M, Chung RT, Graeme-Cook F, Dienstag JL, Bhan AK, Cosimi AB. Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy. Transplantation 1998; 66: 1254-1258 [PMID: 9825826 DOI: 10.1097/00007890-199811 150-00023].
102. Kamar N, Milioto O, Alric L, El Kahwaji L, Cointault O, Lavayssière L, Sauné K, Izopet J, Rostaing L. Entecavir therapy for adefovir-resistant hepatitis B virus infection in kidney and liver allograft recipients. Transplantation 2008; 86: 611-614 [PMID: 18724232 DOI: 10.1097/TP.0b013e3181806c8c].
103. Tse KC, Yap DY, Tang CS, Yung S, Chan TM. Response to adefovir or entecavir in renal allograft recipients with hepatitic flare due to lamivudine-resistant hepatitis B. Clin Transplant 2010; 24: 207-212 [PMID: 19758269 DOI: 10.1111/j.1399-0012.2009.01090.x].
104. Ridruejo E AR, Alonso C, Mandó OG, Silva MO Entecavir in the treatment of chronic hepatitis B in end stage renal disease and kidney transplantation. Dial Transplant 2010; (39): 397-400 [DOI: 10.1002/dat.20485].
105. Yap DY, Tang CS, Yung S, Choy BY, Yuen MF, Chan TM. Long-term outcome of renal transplant recipients with chronic hepatitis B infection-impact of antiviral treatments. Transplantation 2010; 90: 325-330 [PMID: 20562676 DOI: 10.1097/TP.0b013e3181e5b811].
106. Ridruejo E, Adrover R, Mandó OG, Silva MO. Entecavir in the treatment of chronic hepatitis B in kidney transplantation. J Hepatol 2012; 56: 997-998; author reply 999 [PMID: 22075262 DOI: 10.1016/j.jhep.2011.09.019].
107. Chan TM, Tse KC, Tang CS, Lai KN, Ho SK. Prospective study on lamivudine-resistant hepatitis B in renal allograft recipients. Am J Transplant 2004; 4: 1103-1109 [PMID: 15196068 DOI: 10.1111/j.1600-6143.2004.00467.x].
108. Daudé M, Rostaing L, Sauné K, Lavayssière L, Basse G, Esposito L, Guitard J, Izopet J, Alric L, Kamar N. Tenofovir therapy in hepatitis B virus-positive solid-organ transplant recipients. Transplantation 2011; 91: 916-920 [PMID: 21325995 DOI: 10.1097/TP.0b013e3182100f59].
109. Amarapurkar DN, Patel N. Increased eGFR with telbivudine in combination therapy of chronic hepatitis B infection. Indian J Gastroenterol 2014; 33: 89-91 [PMID: 23512213].
110. Piratvisuth T, Komolmit P, Tanwandee T, Sukeepaisarnjaroen W, Chan HL, Pessôa MG, Fassio E, Ono SK, Bessone F, Daruich J, Zeuzem S, Cheinquer H, Pathan R, Dong Y, Trylesinski A. 52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic hepatitis B. PLoS One 2013; 8: e54279 [PMID: 23390496 DOI: 10.1371/journal.pone.0054279].
111. Wang Y, Thongsawat S, Gane EJ, Liaw YF, Jia J, Hou J, Chan HL, Papatheodoridis G, Wan M, Niu J, Bao W, Trylesinski A, Naoumov NV. Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat 2013; 20: e37-e46 [PMID: 23490388 DOI: 10.1111/jvh.12025].
112. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374 [PMID: 19330875 DOI: 10.1002/hep.22759].
113. Baid S, Cosimi AB, Tolkoff-Rubin N, Colvin RB, Williams WW, Pascual M. Renal disease associated with hepatitis C infection after kidney and liver transplantation. Transplantation 2000; 70: 255-261 [PMID: 10933143 DOI: 10.1097/0000789 0-200007270-00001].
114. Baid S, Tolkoff-Rubin N, Saidman S, Chung R, Williams WW, Auchincloss H, Colvin RB, Delmonico FL, Cosimi AB, Pascual M. Acute humoral rejection in hepatitis C-infected renal transplant recipients receiving antiviral therapy. Am J Transplant 2003; 3: 74-78 [PMID: 12492714 DOI: 10.1034/j.1600-6143.2003.30113.x].
115. Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: benefits of antiviral therapy. J Hepatol 2012; 57: 442-450 [PMID: 22504333 DOI: 10.1016/j.jhep.2012.02.033].
116. Vezali E, Aghemo A, Colombo M: A review of the treatment of chronic hepatitis C virus infection in cirrhosis. Clin Ther 2010; 32: 2117-2138 [DOI: 10.1016/S0149-2918(11)00022-1].
117. Vallet-Pichard A, Pol S. Hepatitis C virus infection in hemodialysis patients. Clin Res Hepatol Gastroenterol 2013; 37: 340-346.
118. Fontaine H, Vallet-Pichard A, Equi-Andrade C, Nalpas B, Verkarre V, Chaix ML, Lebray P, Sobesky R, Serpaggi J, Kreis H, Pol S. Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C. Transplantation 2004; 78: 853-857 [PMID: 15385804 DOI: 10.1097/01.TP.0000128911.87538.AA].
119. Mahmoud IM, Sobh MA, El-Habashi AF, Sally ST, El-Baz M, El-Sawy E, Ghoneim MA. Interferon therapy in hemodialysis patients with chronic hepatitis C: study of tolerance, efficacy and post-transplantation course. Nephron Clin Pract 2005; 100: c133-c139 [PMID: 15855796 DOI: 10.1159/000085442].
120. Ozdemir BH, Ozdemir FN, Sezer S, Colak T, Haberal M. De novo glomerulonephritis in renal allografts with hepatitis C virus infection. Transplant Proc 2006; 38: 492-495 [PMID: 16549157 DOI: 10.1016/j.transproceed.2005.12.109].
121. Recommendations for incorporating human immunodeficiency virus (HIV) prevention into the medical care of persons living with HIV. Clin Infect Dis 2004; 38: 104-121 [PMID: 14679456 DOI: 10.1086/380131].
122. Pipili C, Cholongitas E, Papatheodoridis G. Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther 2014; 39: 35-46 [PMID: 24299322 DOI: 10.1111/apt.12538].
123. Cholongitas E, Papatheodoridis GV, Burroughs AK. Liver grafts from anti-hepatitis B core positive donors: a systematic review. J Hepatol 2010; 52: 272-279 [PMID: 20034693 DOI: 10.1016/j.jhep.2009.11.009].
124. Bortoluzzi I, Gambato M, Albertoni L, Mescoli C, Pacenti M, Cusinato R, Germani G, Senzolo M, Rugge M, Boccagni P, Zanus G, Cillo U, Burra P, Russo FP. Use of grafts from anti-HBc-positive donors in liver transplantation: a 5-year, singlecenter experience. Transplant Proc 2013; 45: 2707-2710 [PMID: 24034028 DOI: 10.1016/j.transproceed.2013.07.049].
125. Franchello A, Ghisetti V, Marzano A, Romagnoli R, Salizzoni M. Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transpl 2005; 11: 922-928 [PMID: 16035057 DOI: 10.1002/lt.20471].
126. Li Z, Hu Z, Xiang J, Zhou J, Yan S, Wu J, Zhou L, Zheng S. Use of hepatitis B surface antigen-positive grafts in liver transplantation: a matched analysis of the US National database. Liver Transpl 2014; 20: 35-45 [PMID: 24142889].
127. Loggi E, Micco L, Ercolani G, Cucchetti A, Bihl FK, Grazi GL, Gitto S, Bontadini A, Bernardi M, Grossi P, Costa AN, Pinna AD, Brander C, Andreone P. Liver transplantation from hepatitis B surface antigen positive donors: a safe way to expand the donor pool. J Hepatol 2012; 56: 579-585 [PMID: 22027583 DOI: 10.1016/j.jhep.2011.09.016].
128. Choi Y, Choi JY, Yi NJ, Lee K, Mori S, Hong G, Kim H, Park MS, Yoo T, Suh SW, Lee HW, Lee KW, Suh KS. Liver transplantation for HBsAg-positive recipients using grafts from HBsAg-positive deceased donors. Transpl Int 2013; 26: 1173-1183 [PMID: 24131436 DOI: 10.1111/tri.12177].
129. De Feo TM, Grossi P, Poli F, Mozzi F, Messa P, Minetti E, Sandrini S, Boschiero L, Rigotti P, Maresca C, Rolla D, Chiaramonte S, Gotti E, Caldara R, Briano G, Scalamogna M. Kidney transplantation from anti-HBc+ donors: results from a retrospective Italian study. Transplantation 2006; 81: 76-80 [PMID: 16421480 DOI: 10.1097/01.tp.0000189930.89031.1b].
130. Jiang H, Wu J, Zhang X, Wu D, Huang H, He Q, Wang R, Wang Y, Zhang J, Chen J. Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: a prospective nonrandomized controlled study from a single center. Am J Transplant 2009; 9: 1853-1858 [PMID: 19538486 DOI: 10.1111/j.1600-6143.2009.02707.x].
131. Berber I, Aydin C, Yigit B, Turkmen F, Titiz IM, Altaca G. The effect of HBsAg-positivity of kidney donors on longterm patient and graft outcome. Transplant Proc 2005; 37: 4173-4175 [PMID: 16387070 DOI: 10.1016/j.transproceed.200 5.10.094].
132. álvaro E, Abradelo M, Fuertes A, Manrique A, Colina F, Alegre C, Calvo J, García M, García-Sesma A, Cambra F, Sanabria R, Moreno E, Jimenez C. Liver transplantation from anti-hepatitis C virus-positive donors: our experience. Transplant Proc 2012; 44: 1475-1478 [PMID: 22841188 DOI: 10.1016/j.transproceed.2012.05.012].
133. Ballarin R, Cucchetti A, Spaggiari M, Montalti R, Di Benedetto F, Nadalin S, Troisi RI, Valmasoni M, Longo C, De Ruvo N, Cautero N, Cillo U, Pinna AD, Burra P, Gerunda GE. Longterm follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. Transplantation 2011; 91: 1265-1272 [PMID: 21478815 DOI: 10.1097/TP.0b013e318219eb8f].
134. Abbott KC, Lentine KL, Bucci JR, Agodoa LY, Peters TG, Schnitzler MA. The impact of transplantation with deceased donor hepatitis c-positive kidneys on survival in wait-listed long-term dialysis patients. Am J Transplant 2004; 4: 2032-2037 [PMID: 15575906 DOI: 10.1046/j.1600-6143.2004.00606.x].
135. Sureshkumar KK, Thai NL, Marcus RJ. Kidney transplantation in hepatitis C-positive recipients: does type of induction influence outcomes? Transplant Proc 2012; 44: 1262-1264 [PMID: 22663997 DOI: 10.1016/j.transproceed.2011.12.076].
136. Flohr TR, Bonatti H, Hranjec T, Keith DS, Lobo PI, Kumer SC, Schmitt TM, Sawyer RG, Pruett TL, Roberts JP, Brayman KL. Elderly recipients of hepatitis C positive renal allografts can quickly develop liver disease. J Surg Res 2012; 176: 629-638 [PMID: 22316669 DOI: 10.1016/j.jss.2011.10.028].
137. Pereira BJ, Wright TL, Schmid CH, Levey AS. A controlled study of hepatitis C transmission by organ transplantation. The New England Organ Bank Hepatitis C Study Group. Lancet 1995; 345: 484-487 [DOI: 10.1016/S0140-6736(95)90583-9].